Cargando…
Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
INTRODUCTION: Patients receiving statin therapy for dyslipidaemia often require treatment with an additional agent to control triglyceride levels. Options for add-on therapy include fibrates and omega-3 fatty acids. This case series describes the effects of switching add-on therapy from fenofibrate...
Autor principal: | Castaldo, Richard S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801984/ https://www.ncbi.nlm.nih.gov/pubmed/27065746 http://dx.doi.org/10.1007/s40267-016-0288-3 |
Ejemplares similares
-
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl
por: Hassan, Amir, et al.
Publicado: (2014) -
Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
por: Crandell, James R.
Publicado: (2016) -
Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014) -
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)